Latest Breaking News On - ஓநாய் பாபர் - Page 1 : comparemela.com

Share this article Share this article NEW YORK, April 7, 2021 /PRNewswire/ Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of FibroGen, Inc. (NASDAQ: FGEN) common stock. FibroGen is a biopharmaceutical company. One of its lead drugs is roxadustat, which promotes red blood cell production. Roxadustat is currently approved for sale in China, Japan and Chile for treatment of anemia for patients with chronic kidney disease. FibroGen submitted a New Drug Application (NDA) to the FDA for roxadustat in December 2019. On March 1, 2021, the FDA informed FibroGen that the Cardiovascular and Renal Drugs Advisory Committee would hold an advisory committee meeting to review the NDA for roxadustat. That news was unexpected and caused FibroGen s stock price to fall almost 25% to $38.07 per share.

New yorkUnited statesAdam feuersteinJoshuaw ruthizerWolf popperJoshua ruthizerFibrogen incRenal drugs advisory committeePrnewswire wolf popperAdvisory committeeNew drug applicationPrior results do not guaranteeபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்ஆடம் பேஉேர்சித்தேன்ஓநாய் பாபர்